Allopregnanolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone

  title={Allopregnanolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone},
  author={Lotta Andr{\'e}en and Inger Sundstr{\"o}m-Poromaa and Marie Bixo and Sigrid Nyberg and Torbj{\"o}rn B{\"a}ckstr{\"o}m},
RationaleAllopregnanolone effects on mood in postmenopausal women are unclear thus far.ObjectivesAllopregnanolone is a neuroactive steroid with contradictory effects. Anaesthetic, sedative, and anxiolytic as well as aggressive and anxiogenic properties have been reported. The aim of this study is to compare severity of negative mood between women receiving different serum allopregnanolone concentrations during progesterone treatment.Materials and methodsA randomized, placebo-controlled, double… 

Allopregnanolone serum concentrations and neurosteroid sensitivity during withdrawal from postmenopausal hormone therapy

The study indicates that withdrawal from E2-only treatment might change neurosteroid sensitivity, whereas the immediate withdrawal from the combined E2 + P results in unchanged neurosteroids sensitivity.

Allopregnanolone and mood disorders

Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy

Among women receiving MPA for 2 weeks after discontinuation of estradiol, depressive symptoms did not emerge, suggesting that, even among women who are currently experiencing depression, brief treatment with MPA is unlikely to disrupt mood.

Menstrual phase, depressive symptoms, and allopregnanolone during short-term smoking cessation.

Changes in ALLO by menstrual phase during short-term smoking cessation among women with and without depressive symptoms are characterized to understand how ALLO varies during smoking changes in clinical samples with depressive symptoms given they are at high risk of smoking relapse.

Allopregnanolone decrease with symptom improvement during placebo and gonadotropin-releasing hormone agonist treatment in women with severe premenstrual syndrome

Treatment response, whether induced by buserelin or placebo, appears to be associated with a decrease in allopregnanolone concentration, which was associated with improvement in symptoms compared with pre-treatment ratings.

GABAA Receptor-Modulating Steroids in Relation to Women’s Behavioral Health

In certain women, increased negative mood relates to the progesterone metabolite, allopregnanolone (allo), during the luteal phase of ovulatory menstrual cycles, the premenstrual dysphoric disorder (PMDD), and this effect can be induced by all GABAA receptor modulators in low concentrations whereas higher concentrations are calming.

A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder

Allopregnanolone, a GABAA receptor agonist, decreases gonadotropin levels in women. A preliminary study

The results suggest a regulatory mechanism on the hypothalamic-pituitary-gonadal axis by allopregnanolon and reduces FSH and LH levels in women and the effect might be mediated via a specific GABAA receptor activation since isoallopRegnanolone lacked this effect.



The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy

  • I. BjörnM. Bixo T. Bäckström
  • Medicine, Psychology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2002
It is found that physical symptoms did not differ between 10 and 20 mg MPA, and the aim to lower MPA doses in HRT is unwarranted.

Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy.

The conclusion is that an increase of the estrogen dose accentuates negative mood and physical symptoms during the progestin phase of sequential hormonal therapy.

Progesterone effects during sequential hormone replacement therapy.

In women without prior PMS natural progesterone caused negative mood effects similar to those induced by synthetic progestogens.

Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.

It is demonstrated that although men show an age-related decrease, serum allopregnanolone levels in women do not change with age and correlate with P levels during the menstrual cycle and in response to endocrine tests.

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.

The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome

The symptoms were similar to the typical complaints of the premenstrual syndrome, such that a combination of oestradiol and testosterone implants with cyclical oral norethisterone appears to be a model for this condition.

Negative mood changes during hormone replacement therapy: a comparison between two progestogens.

The addition of medroxyprogesterone to estrogen is preferable to norethindrone with respect to mood symptoms in women without a history of premenstrual syndrome.

Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers.

Plasma allopregnanolone and pregnanolone was significantly correlated with measures of fatigue, confusion and immediate recall, and these correlation coefficients were somewhat greater than those for plasma progesterone and these same behavioral measures.